Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.7800
-0.0349 (-4.28%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Sangamo Therapeutics stock have an average target of 5.17, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 562.82% from the current stock price of 0.78.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,182.05% | Apr 7, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +156.41% | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,182.05% | Jan 27, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +541.03% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,182.05% | Jan 2, 2025 |
Financial Forecast
Revenue This Year
61.16M
from 57.80M
Increased by 5.81%
Revenue Next Year
69.84M
from 61.16M
Increased by 14.19%
EPS This Year
-0.46
from -0.49
EPS Next Year
-0.35
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 113.4M | 119.7M | 477.8M | ||
| Avg | 61.2M | 69.8M | 204.6M | ||
| Low | 14.6M | 9.7M | 51.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 96.2% | 95.7% | 584.1% | ||
| Avg | 5.8% | 14.2% | 193.0% | ||
| Low | -74.7% | -84.1% | -27.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.22 | 1.08 | ||
| Avg | -0.46 | -0.35 | 0.04 | ||
| Low | -0.54 | -0.49 | -0.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.